Seralutinib

DB18072InvestigationalSmall molecule

Seralutinib: Overview.

Mechanism: Pharmacologically active on Mast/stem cell growth factor receptor Kit and Macrophage colony-stimulating factor 1 receptor
Curator reviewed
Formula / weight: C₂₇H₂₇N₅O₃ · 469.545 g/mol (avg)
Also known as: 3-pyridinecarboxamide, n-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl- · N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-3-pyridinecarboxamide
Code names: GB-002 · PK-10571

Resolves to

Compound

Structure

InChIKeyJHJNPOSPVGRIAN-SFHVURJKSA-NSMILESCOC1=CC=C(C=C1OC)C1=CN=CC(N[C@@H](C)C2=CC=CC(NC(=O)C3=CN=CC(C)=C3)=C2)=N1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Seralutinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.